IBD is known to be associated with an abnormal response to an unbalanced gut microbiota in genetically predisposed individuals. The therapeutic goal now is to control progression of the disease. Given the heterogeneity of IBD, the two universes of basic and clinical science must work in parallel to realize the hope of personalized therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033–2045 (2009).
Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259–263 (2008).
Adolph, T. E. et al. Paneth cells as a site of origin for intestinal inflammation. Nature 503, 272–276 (2013).
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229–241 (2004).
Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371–1375 (2010).
Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15, 382–392 (2014).
Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).
Lee, J. C. et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J. Clin. Invest. 121, 4170–4179 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.-F.C. has served as consultant, advisory board member or speaker for Abbvie, ABScience, Amgen, Bristol Meyers Squibb, Celltrion, Danone, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen, Immune Pharmaceuticals, Merck, Millenium Pharmaceuticals, Nutrition Science Partners, Pfizer. Prometheus Laboratories, Protagonist Therapeutics, Receptos, Sanofi, Schering Plough, Second Genome, Takeda, Teva Pharmaceuticals, UCB Pharma, Vertex and Dr August Wolff.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Colombel, JF. IBD—genes, bacteria and new therapeutic strategies. Nat Rev Gastroenterol Hepatol 11, 652–654 (2014). https://doi.org/10.1038/nrgastro.2014.170
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.170
- Springer Nature Limited
This article is cited by
-
Smoking and microbiome in oral, airway, gut and some systemic diseases
Journal of Translational Medicine (2019)